{"search_session":{},"preferences":{"l":"ru","queryLanguage":"ru"},"patentId":"EP_2921857_A1","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"073-955-936-559-099"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11785,"type":"PATENT","title":"Medical University of Vienna Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":420,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8418,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately:Med* Univ* wien. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 364
Search Applicants and Owners separately:Med* Univ* wien. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 364
- determining the amount of soluble AXL in a sample from said patient; and
- assessing that said patient suffers from liver cancer or is prone to suffering from liver cancer when the amount of soluble AXL is increased in comparison to a control."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein said liver cancer is hepatocellular carcinoma."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 2, wherein said amount of soluble AXL in a sample from said patient is at least about 14 ng/ml."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 2, wherein said hepatocellular carcinoma is very early hepatocellular carcinoma, like stage 0 hepatocellular carcinoma."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The method of any one of claim 4, wherein said amount of soluble AXL in a sample from said patient is about 18 ng/ml."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 2, wherein said hepatocellular carcinoma is early hepatocellular carcinoma, like stage A hepatocellular carcinoma."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 6, wherein said amount of soluble AXL in a sample from said patient is about 16 ng/ml."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 2, wherein said hepatocellular carcinoma is advanced hepatocellular carcinoma, like stage B, C or D hepatocellular carcinoma."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 8, wherein said amount of soluble AXL in a sample from said patient is higher than about 18 ng/ml."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The method of any one of claims 2 to 9, wherein said amount of soluble AXL in a control is about 13 ng/ml."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The method of any one of claims 1 to 10, wherein said method further comprises assessing the amount of alpha-fetoprotein (AFP) in a sample from said patient, wherein said amount of alpha-fetoprotein (AFP) in a sample from said patient is lower than about 20 ng/ml; or wherein said amount of alpha-fetoprotein (AFP) in a sample from said patient is higher than about 20 ng/ml."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["The method of any one of claims 1 to 11, wherein soluble AXL is selected from the group consisting of
(a) a polypeptide comprising an amino acid encoded by a nucleic acid molecule having the nucleic acid sequence as depicted in SEQ ID NO: 3;
(b) a polypeptide having an amino acid sequence as depicted in SEQ ID NO:4;
(c) a polypeptide encoded by a nucleic acid molecule encoding a peptide having an amino acid sequence as depicted in SEQ ID NO:4;
(d) a polypeptide comprising an amino acid encoded by a nucleic acid molecule hybridizing under stringent conditions to the complementary strand of nucleic acid molecules as defined in (a) or (c);
(e) a polypeptide having at least 70 % identity to the polypeptide of any one of (a) to (d); and
(f) a polypeptide comprising an amino acid encoded by a nucleic acid molecule being degenerate as a result of the genetic code to the nucleotide sequence of a nucleic acid molecule as defined in (a), (c) and (d)."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["The method of any one of claim 11 or 12, wherein AFP is selected from the group consisting of
(a) a polypeptide comprising an amino acid encoded by a nucleic acid molecule having the nucleic acid sequence as depicted in SEQ ID NO: 5;
(b) a polypeptide having an amino acid sequence as depicted in SEQ ID NO:6;
(c) a polypeptide encoded by a nucleic acid molecule encoding a peptide having an amino acid sequence as depicted in SEQ ID NO:6;
(d) a polypeptide comprising an amino acid encoded by a nucleic acid molecule hybridizing under stringent conditions to the complementary strand of nucleic acid molecules as defined in (a) or (c);
(e) a polypeptide having at least 70 % identity to the polypeptide of any one of (a) to (d); and
(f) a polypeptide comprising an amino acid encoded by a nucleic acid molecule being degenerate as a result of the genetic code to the nucleotide sequence of a nucleic acid molecule as defined in (a), (c) and (d)."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["The method of any one of claims 1 to 13, wherein said sample is a blood sample, such as a serum sample, a plasma sample or a peripheral blood sample."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["The method of any one of claims 1 to 14, wherein the amount of said soluble AXL and/or AFP is determined by protein detection/quantifiying techniques like ELISA (such as Sandwich ELISA), immunohistochemistry (IHC), by immunoassay, gel- or blot-based methods, IHC, mass spectrometry, flow cytometry, or FACS."],"number":15,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}